JPRN-C000000130已完成2 期
Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer - Topotecan and amrubicin for metastatic or relapsed small-cell lung cancer
Okayama Lung Cancer Study Group0 个研究点目标入组 30 人开始时间: 2005年9月12日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
This phase II study showed the favorable efficacy and moderate safety profiles of a topotecan and amrubicin two-drug combination especially in relapsed patients with ED-SCLC.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Severe active infection Other severe complications Pregnant or lactating women Inappropriate condition for this study judged by physicians.
研究者
相似试验
已完成
2 期
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialEpithelial Ovarian CancerNCT01630018Chong Kun Dang Pharmaceutical141
已完成
2 期
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small CellNCT00305942SCRI Development Innovations, LLC61
已完成
2 期
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27
已完成
2 期
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaMyelomaNCT01039025M.D. Anderson Cancer Center60
已完成
2 期
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsGastrinomaRecurrent Islet Cell CarcinomaPancreatic Polypeptide TumorInsulinomaGlucagonomaRecurrent Pancreatic CancerSomatostatinomaStage III Pancreatic CancerStage IV Pancreatic CancerNCT01525082Shaheen Shagufta20